Clinical Trials in Pennsylvania

Showing 6341-6360 of 19,675 trials

Randomized Trial of a Data-driven Technical Assistance System for Drug Prevention Coalitions

NCT04592120

This project is designed to test the Coalition Check-Up (CCU)-a theory-based and data-driven technical assistance (TA) system that supports community coalitions' implementation of evidence-based programs (EBPs) for drug prevention. The primary aims of the project are to: 1) Estimate the impact of the CCU on coalition capacity. Coalitions will be randomly assigned to the CCU or a 'TA as usual' condition to evaluate whether the CCU improves coalition capacity as measured by coalition member reports of team processes, network composition, and collaborative structure. 2) Estimate the impact of the CCU on implementation of evidence-based programs. The study will test the hypothesis that coalitions receiving the CCU will implement EBPs with greater: a) quantity, b) quality, and c) sustainability. The study will also test coalition capacity as a mediator of CCU impact on EBP implementation. 3) Estimate the impact of the CCU on youth substance use. The study will test the hypothesis that communities receiving the CCU will reduce youth substance use relative to communities in the comparison condition. The study will also test EBP implementation as a mediator of CCU impact on youth substance use.

Substance UseAdolescent Problem Behavior

The University of Texas Health Science Center, Houston68 participantsStarted Oct 2020

University Park, Pennsylvania, United States

COMPLETEDPhase 240 miles

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

NCT03233204

This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body (advanced) and have come back (relapsed) or do not respond to treatment (refractory). Olaparib is an inhibitor of PARP, an enzyme that helps repair DNA when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+33 more

National Cancer Institute (NCI)6 participantsStarted Sep 2017

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Mesa, Arizona, United States +110 more locations

Randomized Trial of a Data-driven Technical Assistance System for Drug Prevention Coalitions

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Find Trials by Condition in Pennsylvania

Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

A Phase III Trial of e-TNS for the Acute Treatment of Migraine

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Comparison of Left Bundle Branch Area Versus Right Ventricular Septal Pacing in Patients With High-degree Conduction Disease After Transcatheter Aortic Valve Replacement (Left Bundle BRAVE)

Osia 2 Pediatric Expansion Study

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Comprehensive Outcomes for After Cancer Health

SpineJack System Postmarket Registry

De-Implementation of Unnecessary Surgical Antibiotic Prophylaxis in Children

Brief Cognitive Behavioral Therapy Replication Trial

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)